Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT - Get Free Report) shares traded down 11.7% during mid-day trading on Thursday . The stock traded as low as $2.68 and last traded at $2.72. 325,998 shares were traded during trading, a decline of 73% from the average session volume of 1,212,389 shares. The stock had previously closed at $3.08.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on the stock. Weiss Ratings restated a "sell (e)" rating on shares of Zhengye Biotechnology in a research note on Saturday, September 27th. Wall Street Zen upgraded shares of Zhengye Biotechnology to a "hold" rating in a research note on Saturday, August 2nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of "Sell".
View Our Latest Research Report on Zhengye Biotechnology
Zhengye Biotechnology Price Performance
The firm's 50-day simple moving average is $6.90 and its 200 day simple moving average is $7.15.
Institutional Investors Weigh In On Zhengye Biotechnology
Hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC bought a new stake in Zhengye Biotechnology in the second quarter worth about $174,000. Invesco Ltd. bought a new stake in Zhengye Biotechnology in the second quarter worth about $220,000. Finally, Jane Street Group LLC bought a new stake in Zhengye Biotechnology in the second quarter worth about $1,158,000.
Zhengye Biotechnology Company Profile
(
Get Free Report)
Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zhengye Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zhengye Biotechnology wasn't on the list.
While Zhengye Biotechnology currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
